Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

Por Ko, A H, Hwang, J, Venook, A P, Abbruzzese, J L, Bergsland, E K, Tempero, M A
Publicado em 2005

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

Por Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T
Publicado em 2013

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

Por Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K
Publicado em 2013